论文部分内容阅读
目的:观察不同剂量阿托伐他汀预防造影剂肾病的差异。方法:选取2013年-2014年于粤北人民医院行择期冠脉介入术的心绞痛病人120例,随机分为低剂量组(58例)和高剂量组(62例)。观察两组术前、术后血清肌酐及肝功能变化。结果:高剂量组与低剂量组术后肌酐对比(109.01±56.89 vs 124.30±34.16,P=0.043)及发生造影剂肾病人数1/62(1.61%)明显低于7/58(12.07%),差异均有统计学意义(P<0.05),而两组术后谷草转氨酶(27.57±6.23 vs28.41±5.87,P=0.065)及谷丙转氨酶(27.74±6.09 vs 27.98±6.27,P=0.066)差异均无统计学意义(P>0.05)。结论:高剂量组较低剂量组可更好降低造影剂肾病的发生,且均对近期肝功能影响无差异。
Objective: To observe the difference of atorvastatin with different dosages in preventing contrast-induced nephropathy. Methods: A total of 120 patients with angina pectoris undergoing elective coronary intervention in Guangdong North People’s Hospital from 2013 to 2014 were randomly divided into low dose group (58 cases) and high dose group (62 cases). Preoperative and postoperative serum creatinine and liver function were observed. Results: The postoperative creatinine (109.01 ± 56.89 vs 124.30 ± 34.16, P = 0.043) and 1/62 (1.61%) patients with contrast agent nephropathy were obviously lower than 7/58 (12.07%) in high dose group and low dose group, (27.57 ± 6.23 vs 28.41 ± 5.87, P = 0.065) and alanine aminotransferase (27.74 ± 6.09 vs 27.98 ± 6.27, P = 0.066) in the two groups after operation There was no significant difference (P> 0.05). CONCLUSION: Compared with the low dose group, the high dose group can reduce the incidence of contrast agent nephropathy, and both have no difference in recent liver function.